Abstract:Objective:To explore the efficacy and safety of non-myeloablative autologous peripheral hematopoietic stem cell (HSC) and single allogeneic umbilical cord mesenchymal stem cell (MSC) transplantation in the treatment of patients with type 1 diabetes mellitus (T1DM).Methods:This was a retrospective case-control study. Nine participants receiving HSC transplantation and 8 participants receiving MSC transplantation during August 2006 and December 2010 in Department of Endocrinology, Nanjing Drum Tower Hospital Clinical College of Xuzhou Medical University were selected for analysis, meanwhile 10 matched participants who received insulin therapy alone during the same time period were enrolled as the control. Insulin injection dose, glycated hemoglobin A 1c (HbA 1c), fasting C-peptide (FCP) and 2h-postprandial C-peptide (2hCP) were collected before and 12 months after transplantation, and the change range of each index was calculated. Clinical remission was defined as a 10% increase from baseline in the levels of FCP and/or 2hCP. The adverse reactions of patients during the two kinds of stem cell transplantation and follow-up were observed to judge their safety. T-test, one-way analysis of variance, Mann-Whitney U test, Kruskal-Wallis H test, Fisher′s exact test were used to compare between the groups. Results:At the 12 th month of follow-up, the ratio of clinical remission in the HSC-treated, MSC-treated and control group were 7/9, 2/8, and 1/10 respectively, with HSC-treated group showing significantly higher ratio than that of control group ( P=0.005). By the end of follow-up, the HbA 1c of the three groups were (6.5±1.3)%, (7.7±1.5)% and (9.2±3.5)%, respectively. The decrease of insulin injection dose and increase of FCP in HSC transplantation group were significantly higher than those in control group, and the increase of 2hCP in HSC transplantation group was significantly higher than that in MSC transplantation group and control group ( P<0.05). Two recipients of HSC-treated group achieved insulin independence, but none in the MSC-treated group or control group. Compared to baseline in each group, HbA 1c ( t=-3.85, P=0.008) and insulin injection dose ( t=-2.47, P=0.039) were decreased and 2hCP ( Z=-2.07, P=0.039) were increased at the end of follow-up in HSC-treated group, while HbA 1c ( t=-3.11, P=0.017) and 2hCP ( Z=-2.38, P=0.016) were decreased in MSC-treated group. Considering the safety of stem cell transplantation, all recipients in the HSC-treated group experienced some adverse events, while none presented in the MSC-treated group. Conclusions:Both stem cell therapies improved glycemic control and preserved residue β-cell function in T1DM patients. HSC transplantation had a tendency to be superior to MSC transplantation in improving β-cell function, while the latter presented a higher safety profile.

Investigation on Clinical Application and Management of Human Islet Allo-Transplantation for Type 1 Diabetes Mellitus

Influence of duration of type 1 diabetes on long-term pancreatic transplant outcomes.

Systematic Review of Clinical Application Effect of Islet Allotransplantation for Type 1 Diabetes

Allograft Islet Cell Transplantation and Postoperatively Modified Edmonton Protocol for 3 Cases of Type 1 Diabetes Mellitus

Clinical Researches on Islet Transplantation in 20 Patients with Insulin-Dependent Diabetes Mellitus

Fetal Islet Transplantation In 755 Patients With Insulin-Dependent Diabetes-Mellitus In China

The Fate of Allogeneic Pancreatic Islets following Intraportal Transplantation: Challenges and Solutions

The Influences of Islet Transplantation on Metabolic Abnormalities and Diabetic Complications.

Comparison of the Efficacy and Safety of Non-Myeloablative Autologous Peripheral Hematopoietic Stem Cell and Single Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation in the Treatment of Patients with Type 1 Diabetes Mellitus

Allo-and Xeno-Transplantation of Embryonic Pancreatic Primordia

Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves β-cell function in Chinese patients with new onset of type 1 diabetes

Tolerance induction to islet allografts

Potential roles of mesenchymal stromal cells in islet allo- and xenotransplantation for type 1 diabetes mellitus

Stem Cell Transplantation in the Treatment of Type 1 Diabetes Mellitus: From Insulin Replacement to Beta-Cell Replacement

Immune-Protective Formulations and Process Strategies for Improved Survival and Function of Transplanted Islets

[Research progress on the donor cell sources of pancreatic islet transplantation for treatment of diabetes mellitus]

Pancreatic islet transplantation: current advances and challenges

Improvement of Massive Human Islet Isolation Techniques and the Evaluation of Isolated Human Islets

Clinical Islet Xenotransplantation: Development of Isolation Protocol, Anti-Rejection Strategies, and Clinical Outcomes

Study of Co-Transplantation of Bone Marrow Mesenchymal Cells and Islets for Treating Type 1 Diabetes Mellitus in Sprague-Dawley Rats

Therapeutic effect of autologous hematopoietic stem cell transplantation in one newly-diagnosed type 1 diabetic patient